» Articles » PMID: 35149584

Acute Exacerbations in Children's Interstitial Lung Disease

Abstract

Introduction: Acute exacerbations (AEs) increase morbidity and mortality of patients with chronic pulmonary diseases. Little is known about the characteristics and impact of AEs on children's interstitial lung disease (chILD).

Methods: The Kids Lung Register collected data on AEs, the clinical course and quality of life (patient-reported outcomes - PRO) of rare paediatric lung diseases. Characteristics of AEs were obtained.

Results: Data of 2822 AEs and 2887 register visits of 719 patients with chILD were recorded. AEs were characterised by increased levels of dyspnoea (74.1%), increased respiratory rate (58.6%) and increased oxygen demand (57.4%). Mostly, infections (94.4%) were suspected causing an AE. AEs between two register visits revealed a decline in predicted FEV1 (median -1.6%, IQR -8.0 to 3.9; p=0.001), predicted FVC (median -1.8%, IQR -7.5 to 3.9; p=0.004), chILD-specific questionnaire (median -1.3%, IQR -3.6 to 4.5; p=0.034) and the physical health summary score (median -3.1%, IQR -15.6 to 4.3; p=0.005) compared with no AEs in between visits. During the median observational period of 2.5 years (IQR 1.2-4.6), 81 patients died. For 49 of these patients (60.5%), mortality was associated with an AE.

Conclusion: This is the first comprehensive study analysing the characteristics and impact on the clinical course of AEs in chILD. AEs have a significant and deleterious effect on the clinical course and health-related quality of life in chILD.

Citing Articles

"We Could Hold Our Own Here at Home": Longitudinal Experience of COVID-19 Lockdowns in Parents With Children Affected With Interstitial Lung Disease.

Gilbert C, Bush A, Bennett K, Brown C Pediatr Pulmonol. 2024; 60(1):e27446.

PMID: 39692204 PMC: 11748111. DOI: 10.1002/ppul.27446.


Pulmonary fibrosis may begin in infancy: from childhood to adult interstitial lung disease.

Griese M, Kurland G, Cidon M, Deterding R, Epaud R, Nathan N Thorax. 2024; 79(12):1162-1172.

PMID: 39153860 PMC: 11671978. DOI: 10.1136/thorax-2024-221772.


Innovations in Childhood Interstitial and Diffuse Lung Disease.

Casey A, Fiorino E, Wambach J Clin Chest Med. 2024; 45(3):695-715.

PMID: 39069332 PMC: 11366208. DOI: 10.1016/j.ccm.2024.04.002.


Towards personalized therapies for genetic disorders of surfactant dysfunction.

Peers de Nieuwburgh M, Wambach J, Griese M, Danhaive O Semin Fetal Neonatal Med. 2023; 28(6):101500.

PMID: 38036307 PMC: 10753445. DOI: 10.1016/j.siny.2023.101500.


Emerging Treatments for Childhood Interstitial Lung Disease.

Bernardinello N, Griese M, Borie R, Spagnolo P Paediatr Drugs. 2023; 26(1):19-30.

PMID: 37948041 PMC: 10770003. DOI: 10.1007/s40272-023-00603-9.